Trial · NCT04266301
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sabatolimab (MBG453) + Azacitidine | 265 | |
| Overall Study | STARTED | Placebo + Azacitidine | 265 | |
| Overall Study | Participants Treated | Sabatolimab (MBG453) + Azacitidine | 264 | |
| Overall Study | Participants Treated | Placebo + Azacitidine | 264 | |
| Overall Study | Participants Not treated | Sabatolimab (MBG453) + Azacitidine | 1 | |
| Overall Study | Participants Not treated | Placebo + Azacitidine | 1 | |
| Overall Study | Discontinued from treatment | Sabatolimab (MBG453) + Azacitidine | 264 | |
| Overall Study | Discontinued from treatment | Placebo + Azacitidine | 264 | |
| Overall Study | Entered post-treatment | Sabatolimab (MBG453) + Azacitidine | 68 | |
| Overall Study | Entered post-treatment | Placebo + Azacitidine | 71 | |
| Overall Study | Did not enter post-treatment | Sabatolimab (MBG453) + Azacitidine | 196 | |
| Overall Study | Did not enter post-treatment | Placebo + Azacitidine | 193 | |
| Overall Study | Discontinued from study | Sabatolimab (MBG453) + Azacitidine | 265 | |
| Overall Study | Discontinued from study | Placebo + Azacitidine | 265 | |
| Overall Study | Full Analysis See (FAS) | Sabatolimab (MBG453) + Azacitidine | 265 | |
| Overall Study | Full Analysis See (FAS) | Placebo + Azacitidine | 265 | |
| Overall Study | Safety Set | Sabatolimab (MBG453) + Azacitidine | 263 | |
| Overall Study | Safety Set | Placebo + Azacitidine | 265 | |
| Overall Study | COMPLETED | Sabatolimab (MBG453) + Azacitidine | 0 | |
| Overall Study | COMPLETED | Placebo + Azacitidine | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04266301/flow